HIGH TITER ANA NOT NECESSARILY A VALID CRITERION FOR LUPUS – PROPOSAL OF A MODIFICATION TO THE CRITERIA FOR CLASSIFICATION OF SLE

1Luís EC Andrade, 2Jan Damoiseaux, 3Minoru Satoh, 4Edward KL Chan*. 1Rheumatology Division, Federal University of São Paulo, Brazil; 2Central Diagnostic Laboratory, Maastricht University Medical Centre, The Netherlands; 3Department of Clinical Nursing, University of Occupational and Environmental Health, Kitakyushu, Japan; 4Department of Oral Biology, University of Florida, USA

Background The 1997 Update of the 1982 American College of Rheumatology Revised Criteria for Classification of SLE includes two autoantibody criteria: #10, abnormal level of anti-native DNA, anti-Sm, or antiphospholipid; #11 positive antinuclear antibody (ANA). Thus, ANA positivity is counted as 1 of the 11 criteria and a person shall be said to have SLE if any 4 or more of the 11 criteria are present, serially or simultaneously, during any interval of observation. The immunofluorescence pattern observed in the ANA test provides a direct initial assessment of any 4 or more of the autoimmune rheumatic diseases (SARD). As a follow-up to the International Consensus on ANA Patterns (ICAP) initiative (ANAPatterns.org), which aims to promote harmonisation of ANA pattern nomenclature and provides guidelines for ANA interpretation, thereby optimising usage in patient care, the relevance of each ANA pattern is being re-evaluated.

Methods Collective issues on ANA nomenclature were raised among research, clinical, and diagnostic laboratories represented by two workshop participants and a working committee. Post-workshop exchanges arrived at consensus on a few, but clearly not all, issues. One focus is to establish an interpretative clinical description for each defined ANA pattern for clinical use based on current literature.

Results Consensus was achieved for 28 ICAP patterns designated with alpha-numeric code (AC-1 to AC-28) and summarised under a nomenclature and classification tree categorised in three major groups (nuclear, cytoplasmic, and mitotic patterns). An important observation is that, while the Homogeneous (AC-1) and Coarse Speckled nuclear (AC-5) patterns are linked to autoantibodies strongly associated with SARD, the Dense Fine Speckled (DFS) nuclear pattern (AC-2) virtually rules out a SARD diagnosis. A clear cut DFS pattern is usually present when anti-DFS70/LEDGF/P75 is the only predominant autoantibody in the serum sample. DFS is the most common pattern in high titer ANA-positive, apparently healthy, individuals. Although DFS has been reported in a wide variety of chronic inflammatory diseases, such as Hashimoto’s thyroiditis, atopic dermatitis, interstitial cystitis, Vogt-Koyanagi-Harada syndrome, and in miscellaneous non-inflammatory diseases, it is not associated with SARD, even when present at very high titer.

Conclusions ICAP has clearly provided a common platform to address issues that are of great interest to the ANA community and closely linked to ANA in disease criteria. Evidently, well-defined anti-DFS ANA, confirmed by antigen-specific reflex testing, should not be considered a criterion for SLE – either in the ACR or 2012 SLICC classification criteria.

RESPONSE GENE TO COMPLEMENT-32 PROMOTES PLASMA CELL DIFFERENTIATION AND ENHANCES LUPUS-LIKE CHRONIC GRAFT VERSUS HOST DISEASE

1Alexandru Tatomir, 2Vinh Nguyen, 2Cosmin Tegea, 2Comelia Cudrici, 2Tudor Badea, 1Horea Rus, 1Violeta Rus*. 1University of Maryland School of Medicine; 2VA Maryland Health Care System, Baltimore, MD; 3NIH, National Eye Institute, Bethesda, MD

Background Response Gene to Complement (RGC)–32 is an intracellular protein that plays a role in cell growth and promotes cell cycle activation and Akt phosphorylation. RGC-32 is also a downstream target of TGF-β in fibroblasts and renal proximal tubular cells and plays a role in renal fibrogenesis. In immune cells, RGC-32 is expressed by both T and B lymphocytes. Our prior studies showed that RGC-32 promotes Th17 differentiation of mouse CD4 T cells and is highly expressed in human IL-17 CD4 cells. Whether RGC-32 plays a role in the activation and differentiation of B cells and the development of autoimmunity is not known. We used WT and RGC-32 KO mice to determine whether lack of RGC-32 impairs B cell differentiation and activation and alters autoimmune parameters in the chronic graft versus host disease (cGVHD) model of lupus.

Materials and methods B cells were cultured with lps, anti-CD40 mAb, IL-21 and IL-6, IL-4 or TGFβ and RGC-32 mRNA and protein expression was determined. TLIR-dependent and T independent B cell differentiation to plasma cells (PC) was induced with lps and with CD40mAb plus IL-4. cGVHD was induced with 100×10^6 Bm12 splenocytes injected into WT or RGC-32 KO recipients. Host B cell number and activation, anti-dsDNA Ab production, germinal centre (GC) B cell number and proliferation, PC number, expression of transcription factors IRF4 and Blimp1 were assessed at 2 and 4 weeks.

Results RGC-32 mRNA was upregulated in B cells by lps, anti-CD40 mAb, IL-21 and IL-6. RGC-32 KO B cells failed to differentiate normally to PC as demonstrated by a 2-fold reduction in PC numbers generated after lps and anti-CD40+ IL-4 stimulation and impaired upregulation of Prdm1 and IRF4 mRNA. RGC-32 transcripts were upregulated in spleen cells from cGVHD mice and protein expression was detected in B cells and GC cells. RGC-32KO hosts displayed an attenuated autoimmune phenotype as demonstrated by: 1) decreased production of anti-dsDNA autoAb. 2) decreased number and proliferation of GC B cells. 3) decreased number of IgG anti-dsDNA secreting PC and 4) decreased IRF4 and Prdm1 mRNA expression.

Conclusions These results suggest that expression of RGC-32 in B cells is critical for optimal GC proliferation, PC differentiation and autoantibody production in a murine model of lupus. These data support the idea that RGC-32 blockade has the potential to attenuate autoimmune parameters of cGVHD and possibly reverse abnormalities in the T and B cell pathways that contribute to lupus pathogenesis.

DALAZATIDE, AN INHIBITOR OF THE KV1.3 CHANNEL ON ACTIVATED EFFECTOR MEMORY T CELLS, HAS IMMUNOTHERAPY POTENTIAL AGAINST SYSTEMIC LUPUS ERYTHEMATOSUS

1Anne Stevens*, 2Megan Yuasa, 3David Pedcham, 3Chelsea Olsen, 3Shawn Iadonato, 3Peter Probst. 1Seattle Children’s Research Institute, Seattle, WA, USA; 2University of Washington, Seattle, WA, USA; 3Kineta, Inc., Seattle, WA, USA; 4KPI Therapeutics, Inc., Seattle, WA, USA

Background Dalazatide, an inhibitor of the KV1.3 channel on activated effector memory T cells, has immunotherapeutic potential against systemic lupus erythematosus (SLE) in animal models of lupus. This study evaluated the safety and tolerability of dalazatide in patients with active SLE in a phase 1b safety and pharmacokinetic trial. The primary objective was to determine the maximum tolerated dose (MTD) of dalazatide and to assess its tolerability in patients with active SLE.

Methods In this open-label, single-center study, patients with active SLE were randomized to receive dalazatide at doses of 25, 50, or 100 mg intravenous (IV) infusion over 30 minutes once weekly for 12 weeks. The primary outcome was the incidence of serious adverse events (SAEs) and the number of patients who experienced at least one SAE. Secondary outcomes included changes in disease activity scores and safety assessments.

Results A total of 15 patients were enrolled and received dalazatide at the three dose levels. The most common adverse events were headache, nausea, and dizziness. No dose-limiting toxicity was observed, and the MTD was not reached. The mean change in SLE disease activity index (SLEDAI) was -9.2 at week 12, indicating a significant improvement in disease activity. There were no significant changes in laboratory parameters or other safety parameters.

Conclusions Dalazatide was well tolerated in patients with active SLE and demonstrated significant improvement in disease activity. These results support further evaluation of dalazatide in patients with active SLE to determine its potential as an immunotherapeutic agent.